Colon News and Research

RSS

New research to predict patient response to cancer chemotherapies

Timothy J. Yeatman, M.D., Moffitt's Associate Center Director for Clinical Investigations at the H. Lee Moffitt Cancer Center & Research Institute, and the Sarasota-based DNAPrintTM genomics, Inc., have formed a joint research program to develop and implement new clinical tests for predicting patient response to cancer chemotherapies.

29 Mar 2004

Enzyme called COX-2 may promote the development of ovarian tumors

Fox Chase Cancer Center scientists have identified how an enzyme called COX-2 may promote the development of ovarian tumors, adding further insight into the mechanism of COX-2 inhibitors and the prevention of this highly lethal disease. The data was presented today at the 95th Annual Meeting of the American Association for Cancer Research in Orlando, Fla.

29 Mar 2004

Novel vaccine technology to suppress the growth of certain tumors

MedImmune, Inc. and Cerus Corporation have announced preclinical results demonstrating the effectiveness of a novel therapeutic vaccine technology in suppressing the growth of certain tumors.

From Baxter International Inc. 29 Mar 2004

Halting the development of certain pancreatic, ovarian, colon and lung cancers may be possible with new therapy

By investigating a single molecule that influences cell growth, a research group in the Purdue Cancer Center, including Brian S. Henriksen, has gained new insight into the chain of events that make some cancer cells divide uncontrollably, insight that may eventually lead to a way to break that chain, stopping cancer in its tracks. The molecule, known as Icmt, has a critical role in the development of Ras, an ordinarily beneficial protein that tells a cell to divide. The research group has determined how to inhibit Icmt's influence on Ras, without which the protein cannot develop effectively into an instigator of cell growth.

28 Mar 2004

Research suggests the orlistat drug could be used to fight cancer and obesity

The Burnham Institute’s Jeffrey Smith, Ph.D., has discovered that orlistat, commonly prescribed as an anti-obesity drug, has a positive side-effect: it inhibits cancer growth. Dr. Smith made this discovery using an activity-based proteomics screening technique developed in his laboratory that makes it possible to identify active targets and simultaneously screen for their inhibitors.

22 Mar 2004

New therapies that may treat cancers

Scientists at the Johns Hopkins Kimmel Cancer Center and Howard Hughes Medical Institute have found mutations in a gene linked to the progression of colon and other cancers. The research findings, may lead to new therapies and diagnostic tests that target this gene.

22 Mar 2004

Bacteria Live in the Esophagus!

The esophagus isn't merely a tube for food traveling from the mouth to the stomach, it also provides an environment for bacteria to live, according to a new study by NYU School of Medicine scientists that overturns the general belief that the esophagus is free of bacteria.

22 Mar 2004

Obesity Drug Inhibits Prostate Tumor Growth

The Burnham Institute's Jeffrey Smith, Ph.D. has discovered that orlistat, commonly prescribed as an anti-obesity drug, has a positive side-effect: it inhibits cancer growth. Dr. Smith made this discovery using an activity-based proteomics screening technique developed in his laboratory that makes it possible to identify active targets and simultaneously screen for their inhibitors.

22 Mar 2004